Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11, 2025

The Top 5 Biosimilar Articles for the Week of July 7

July 11, 2025

Two More Pairs of Denosumab Biosimilars Enter US Market

July 09, 2025

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Webinar: Experts Discuss Avenues to Improve Biosimilar Development Efficiency

October 4th 2023

By Skylar Jeremias

Article

A recent webinar featured an in-depth discussion on the impacts that updated guidelines, a reduction in clinical efficacy testing, and biomarker analyses can have on the efficiency of biosimilar development.

BioRationality: Calling on Developers to Help Address Remaining Biosimilar Issues

October 3rd 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, summarized the citizen petitions he's filed to the FDA as well as changes he believes are needed to propel the biosimilar industry into the future, including calling on biosimilar manufacturers to help.

Biosimilars Regulatory Roundup: September 2023

October 2nd 2023

By Skylar Jeremias

Article

September was graced with several regulatory updates from around the world, including some European and Japanese approvals, as well as the FDA’s 2-day workshop on the current science behind clinical efficacy testing for biosimilars and streamlining biosimilar development.

Biosimilars Regulatory Roundup for September 2023—Podcast Edition

October 1st 2023

By Justina Petrullo

Podcast

On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.

Common Patient Questions About Insulin Biosimilars Pertain to Classification

September 30th 2023

By Camlyn Masuda, PharmD, BCACP, CDCES

Article

Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.

The Top 5 Biosimilar Articles for the Week of September 25

September 29th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of September 25, 2023.

Secukinumab Found Cost-Effective for Patients With Moderate to Severe Psoriasis

September 28th 2023

By Justina Petrullo

Article

Compared with other biologics frequently used in China for moderate-to-severe psoriasis, secukinumab is the most cost-effective treatment option.

EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor

September 27th 2023

By Skylar Jeremias

Article

With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.

Study: Multiple Switches Between Infliximab Products May Lead to Higher Rates of Treatment Discontinuation

September 26th 2023

By Skylar Jeremias

Article

Patients with inflammatory bowel disease who underwent a switch from reference infliximab to a biosimilar and then back to the originator were more likely to discontinue their treatment than patients who underwent a single switch from the originator to a biosimilar.

Alvotech’s Stelara Biosimilar Approved in Japan

September 25th 2023

By Skylar Jeremias

Article

Iceland-based Alvotech announced the approval of its ustekinumab biosimilar referencing Stelara in Japan for autoimmune conditions. The company also released an update on the US filing for its adalimumab biosimilar.